Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor
stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies).
PTIS helps prepare the body for the transplant and lowers the risk of developing graft versus
host disease (GVHD). Hematopoietic cells are found in the bone marrow and produce blood
cells. Hematopoietic cell transplantation (HCT) injects healthy hematopoietic cells into the
body to support blood cell production. PTIS and HCT may help to control severe
hemoglobinopathies.